Aurobindo Pharma Limited has announced that its wholly owned subsidiary, CuraTeQ Biologics Private Limited, has received marketing authorisation from the CDSCO for Bevqolva®. This bevacizumab biosimilar is indicated for the treatment of metastatic carcinoma of the colon or rectum. The approval allows for the manufacturing at the company’s Hyderabad facility and the commercial marketing of the drug in two specific vial strengths.
Strategic Approval for Oncology Portfolio
On May 16, 2026, Aurobindo Pharma disclosed that its subsidiary, CuraTeQ Biologics, successfully secured the required marketing authorisation for its new biosimilar product, Bevqolva®. This milestone marks a significant step in the company’s expansion into the biosimilars market, specifically targeting oncology treatments.
Product Specifications and Manufacturing
The authorised drug, Bevqolva®, is a bevacizumab biosimilar designed for patients suffering from metastatic carcinoma of the colon or rectum. Under the terms of the approval, CuraTeQ Biologics is authorised to manufacture the drug at its facility located in Hyderabad. The product will be available for distribution in two distinct presentations: 100 mg/4mL and 400 mg/16 mL vials.
Impact on Clinical Offerings
By securing this marketing authorisation, Aurobindo Pharma enhances its therapeutic offerings in the oncology space. The move underscores the company’s commitment to advancing its biotechnology capabilities and providing cost-effective alternatives for critical medical treatments. This approval follows standard regulatory processes and positions the company to begin commercial-scale supply to the market.
Source: BSE
